CASI Pharmaceuticals Announces CID-103 Update, Acquisition Proposal at $1.15 per Share

CASI Pharmaceuticals announced additional data from its Phase 1 open-label study of CID-103 in adult patients with immune thrombocytopenia. Initial clinical data from this study were presented at the 67th American Society of Hematology Annual Meeting and Exposition on December 7, 2025, in Orlando, Florida. Updated safety and efficacy data can be found on the CASI website here. The update includes additional safety and efficacy data based on: CID-103 at 30 mg, 150 mg, 300 mg, 600 mg and 900 mg; ~5 weeks of additional dosing / follow up for the ongoing patients in all cohorts; 3 additional patients enrolled in 900 mg cohort; 2 patients are at Week 5 of study treatment; 1 patient is at Week 3 of study treatment; 2 additional patients enrolled and one patient is in screening in 600 mg cohort; 1 patient is at Week 3 of study treatment; 1 patient is at Week 2 of study treatment. Interim Results: CID-103 demonstrated a manageable safety profile with only two Grade 3 treatment-related events and no dose limiting toxicities observed; All infusion-related reactions occurred with priming dose and are due to low grade AEs; Primary Efficacy Endpoint achieved in 12 of 15 evaluable patients; 10 of 15 evaluable patients achieved Complete Response with platelet improvement observed as early as one week post dose; Reduction of PD markers (decreased anti-platelet antibodies, immunoglobulins, NK and plasma cells) is consistent with the presumed CID-103 MOA resulting in the observed platelet response Separately, the Company announced that its board of directors received a preliminary non-binding proposal, dated January 7, 2026,which was further amended by an updated preliminary non-binding proposal dated January 9, 2026 from Dr. Wei-Wu He, to acquire all of the outstanding ordinary shares, par value $0.0001 per share, of the Company, that are not already beneficially owned by Dr. He for a proposed purchase price of $1.15 per Ordinary Share. The proposed price represents a 30% premium to the average closing price during the last 30 trading days.